Status: Recruiting
RSV Immunogenicity Study in the Elderly (RISE)
Respiratory syncytial virus (RSV) is a common cause of respiratory tract infections leading to hospitalizations in infants and in elderly. Arexvy is an approved vaccine for the prevention of RSV infection, however, data on its efficacy in individuals aged 80 years and older remain limited. This study aims to evaluate potential differences in immune responses to Arexvy vaccination between adults aged ≥80 years and those aged 60-65 years.
Participants needed: 65
Trial details
Phase: Phase 3Age: 60+Biological sex: AllType: InterventionalSponsor: Karin Karin LoréUpdated: Oct 2, 2025Locations: 2
Eligibility criteria
Male or female individuals who were born between 1965 and 1960 or 1945 and befor... [+5]
Individuals who are medically immunocompromised, less than 2 years since hematop... [+9]